144 related articles for article (PubMed ID: 37183206)
1. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients.
Gu S; Menzer C; Hay JL; Pena C; Dusza S; Lacouture ME; Markova A
Support Care Cancer; 2023 May; 31(6):337. PubMed ID: 37183206
[TBL] [Abstract][Full Text] [Related]
2. Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review.
Shaigany S; Mastacouris N; Tannenbaum R; Strunk A; Luan C; Burshtein J; Burshtein A; Carvajal R; Garg A; Alloo A
JAMA Dermatol; 2024 Jun; 160(6):651-657. PubMed ID: 38506826
[TBL] [Abstract][Full Text] [Related]
3. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
4. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
[TBL] [Abstract][Full Text] [Related]
6. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study.
Kang D; Kim S; Kim H; Lee M; Kong SY; Chang YJ; Sim SH; Kim YJ; Cho J
JMIR Public Health Surveill; 2023 Mar; 9():e44105. PubMed ID: 36884274
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
9. Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Hsu HT; Yu CC; Lee YH; Chan JC; Chu CY
Support Care Cancer; 2022 Nov; 30(11):9211-9219. PubMed ID: 36056941
[TBL] [Abstract][Full Text] [Related]
10. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
11. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A; Cameron MC; Garden B; Boers-Doets CB; Schindler K; Epstein JB; Choi J; Beamer L; Roeland E; Russi EG; Bensadoun RJ; Teo YL; Chan RJ; Shih V; Bryce J; Raber-Durlacher J; Gerber PA; Freytes CO; Rapoport B; LeBoeuf N; Sibaud V; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2231-44. PubMed ID: 25564221
[TBL] [Abstract][Full Text] [Related]
13. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
de Almeida DVP; Anderson JM; Danila DC; Morris MJ; Slovin SF; Abida W; Cohn ED; Baser RE; Scher HI; Autio KA
J Immunother Precis Oncol; 2023 Nov; 6(4):162-169. PubMed ID: 38143953
[TBL] [Abstract][Full Text] [Related]
15. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
Chu CY; Choi J; Eaby-Sandy B; Langer CJ; Lacouture ME
Oncologist; 2018 Aug; 23(8):891-899. PubMed ID: 29650685
[TBL] [Abstract][Full Text] [Related]
17. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
18. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
19. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
Wu J; Liu D; Offin M; Lezcano C; Torrisi JM; Brownstein S; Hyman DM; Gounder MM; Abida W; Drilon A; Harding JJ; Sullivan RJ; Janku F; Welsch D; Varterasian M; Groover A; Li BT; Lacouture ME
Invest New Drugs; 2021 Jun; 39(3):785-795. PubMed ID: 33389388
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
